UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY Patent applications |
Patent application number | Title | Published |
20150018274 | ERYTHROPOIETIN-DERIVED SHORT PEPTIDE AND ITS MIMICS AS IMMUNO/INFLAMMATORY MODULATORS - The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof. | 01-15-2015 |
20140295416 | Novel Method of Cancer Diagnosis and Prognosis and Prediction of Response to Therapy - The invention relates to pharmaceutical compositions comprising of FRY polypeptides and nucleotides, methods to treat cancer, methods to diagnose cancer, and methods to determine the effectiveness of the treatment of cancer, as well as methods to differentiate stem cells. | 10-02-2014 |
20140243381 | FURYL AND THIENYL TRIAZOLE DERIVATIVES AND THERAPEUTIC USES THEREOF - Nitric oxide biosynthesis-inhibiting anti-inflammatory and anti-microbial compounds of Formula (3) and Formula (4) wherein R1 and R2 are independently selected from optionally substituted thienyl, optionally substituted furyl, optionally substituted —CH═CH-thienyl and optionally substituted provided that R2 is substituted with as nitro group | 08-28-2014 |
20140234258 | RNA Interferases and Methods of Use Thereof - The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials. | 08-21-2014 |
20140220108 | COCHLEATE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention provides, in part, cochleate compositions and methods for making and using same. | 08-07-2014 |
20140193878 | MRNA Interferase from Myxococcus Xanthus - A regulated deployment of a toxin gene for developmental programmed cell death in bacteria is described. | 07-10-2014 |
20140170131 | Compositions and Methods for the Treatment and Prevention of Infections Caused by Staphylococcus aureus Bacteria - The present invention relates to antimicrobial deoxyribonuclease-based compositions that inhibit growth and proliferation of | 06-19-2014 |
20140134722 | Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof - The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided. | 05-15-2014 |
20140073560 | CITROBACTER FREUNDII ANTIBACTERIAL AGENTS AND THEIR USE - Provided herein are methods for treating planktonic bacteria or a biofilm. The methods include contacting the planktonic bacteria or biofilm with an effective amount of an isolated | 03-13-2014 |
20140044768 | IMPLANTABLE DEVICES COATED WITH INSULIN-MIMETIC AGENT COMPOSITES AND METHODS THEREOF - The present invention discloses vanadium-based insulin-mimetic agent composite coatings, application of these coatings onto implantable devices, and use of the implantable devices for accelerating osseous healing. The invention also encompasses methods of manufacturing implantable devices coated with vanadium-based insulin-mimetic agent composite coatings and the implantable devices so manufactured. The implantable devices have wide applications, including but not limited to treating bone fracture, bone trauma, arthrodesis, and other bone deficit conditions, as well as bone injuries incurred in military and sports activities. | 02-13-2014 |
20140031933 | IMPLANTABLE DEVICE AND METHOD TO REPLACE THE MENISCUS OF THE KNEE AND OTHER BODY STRUCTURES - A meniscus implant including a c-shaped scaffold having an arcuate middle section extending between an anterior end and a posterior end. A reinforcing network of fibers independent from the scaffold is embedded therein. Fibers of said network fibers exit each end of the scaffold to form respective anterior and posterior attachment segments which extend parallel to a central axis of the scaffold. The network of fibers is configured to convert an axial compressive force on said scaffold to tensile loads on said attachment points. | 01-30-2014 |
20140020138 | TRANSGENIC PLANTS EXPRESSING DISPERSINB - Methods and compositions for producing genetically transformed plants exhibiting antibiofilm activity against bacterial pathogens are disclosed. Bacterial cells and plant transformation vectors include dspB genes encoding DispersinB antibiofilm enzymes of Aggregatibacter actinomycetemcomitans. | 01-16-2014 |
20140011228 | Labeled Biomolecular Compositions and Methods for the Production and Uses Thereof - Disclosed herein is a set of | 01-09-2014 |
20130345164 | TREATMENTS FOR CELLULAR PROLIFERATIVE DISORDERS AND IDENTIFICATION THEREOF - This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment. | 12-26-2013 |
20130323229 | METABOLIC THERAPY FOR OXIDATIVE STRESS IN THE BRAIN THROUGH TARGETED NEURONAL CATABOLISM OF N-ACETYL-ASPARTIC ACID - The present invention provides a novel method of treatment for treating brain disorders that manifest oxidative stress by providing targeted populations of neurons with the ability to catabolize the acetylated amino acid derivative, N-acetylaspatic acid (NAA) and further supply extraphysiological levels of ATP to neurons via the targeted expression of the NAA catabolic enzyme aspartoacylase (ASPA) in neurons and astrocytes. | 12-05-2013 |
20130302889 | Differentiation of Bone Marrow Cells into Neuronal Cells and Uses Therefor - The present invention relates to methods of inducing differentiation of mammalian bone marrow stromal cells into neuronal cells by contacting marrow stromal cells with a neuronal differentiation-inducing compounds. Neuronal differentiation-inducing compounds of the invention include anti-oxidants such as, but not limited to, beta-mercaptoethanol, dimethylsulfoxide, butylated hydroxyanisole, butylated hydroxytoluene, ascorbic acid, dimethylfumarate, and n-acetylcysteine. Once induced to differentiate into neuronal cells, the cells can be used for cell therapy, gene therapy, or both, for treatment of diseases, disorders, or conditions of the central nervous system. | 11-14-2013 |
20130302257 | Compositions and Methods for Delivering Nucleic Acid Molecules and Treating Cancer - The present invention provides compositions and methods for the delivery of nucleic acids to a cell. The present invention additionally provides compositions and methods for the treatment of a disease or disorder, particularly cancer. | 11-14-2013 |
20130287804 | IMMUNOGENIC POLYPEPTIDES HAVING AN IMMUNOGENIC SCAFFOLD PROTEIN AND A LOOP PEPTIDE, PRESENTING A 3074- OR 2219/2557- MONOCLONAL ANTIBODY-TARGETED EPITOPE, WHICH IS PRESENT IN THE HIV GP120 PROTEIN - The present invention is directed to a recombinant immunogenic polypeptide. The polypeptide includes a loop peptide inserted into an immunogenic scaffold protein. The loop polypeptide has an amino acid sequence which presents the 3074 mAb- or the 2219/2557 mAb-targeted epitope of the HIV gp120 protein and not other known epitopes of the HIV gp120 protein. When used as an immunogen, the polypeptide induces an antibody response which neutralizes heterologous HIV-1 viruses in a pattern similar to that observed for the 3074 mAb- or the 2219/2557 mAb-targeted epitope, respectively. Pharmaceutical compositions containing the immunogenic polypeptide as well as methods of making and using it are also disclosed. | 10-31-2013 |
20130273018 | RECOMBINANT HUMAN CLN2 PROTEIN AND METHODS OF ITS PRODUCTION AND USE - The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein. | 10-17-2013 |
20130210872 | COMBINATION THERAPY USING RILUZOLE TO ENHANCE TUMOR SENSITIVITY TO IONIZING RADIATION - Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents. | 08-15-2013 |
20130203623 | METHOD AND KIT FOR CLASSIFYING A PATIENT - Provided is a Suppressive Subtractive Hybridization-Oligonucleotide Microarray (SSH-OM) method for the prediction of treatment response for personalized medicine applications and for the prediction of cancer classes and subclasses. | 08-08-2013 |
20130202536 | FLUOROPHORE CHELATED LANTHANIDE LUMINESCENT PROBES WITH IMPROVED QUANTUM EFFICIENCY - The invention relates to novel luminescent compositions of matter containing a fluorophore, synthetic methods for making the compositions, macromolecular conjugates of the compositions, and the use of the compositions in various methods of detection. The invention also provides kits containing the compositions and their conjugates for use in the methods of detection. | 08-08-2013 |
20130183669 | COMPOSITIONS AND METHODS FOR DIAGNOSING AUTISM - Mutations located within the gene encoding the homeobox transcription factor, ENGRAILED 2 (EN2), have now been identified as molecular markers associated with susceptibility for autism and related disorders. Thus, the present invention relates to compositions in the form of diagnostic kits, primers and target sequences, for use in methods for determining the predisposition, the onset or the presence of autism spectrum disorder in a mammal. Moreover, therapeutic methods for treating a person inflicted with, or predisposed to, an autism spectrum disorder based upon modulating the level or activity of EN2 are also provided. | 07-18-2013 |
20130171094 | USE OF VANADIUM COMPOUNDS TO ACCELERATE BONE HEALING - This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment. | 07-04-2013 |
20130157888 | DIAGNOSTIC AUTOANTIBODY PROFILES FOR THE DETECTION AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES - The present invention provides methods, compositions, and kits for the detection of neurodegenerative disease specific autoantibodies for the diagnosis of neurodegenerative diseases and risk for developing neurodegenerative diseases, and for the generation of patient-specific neurodegenerative disease diagnostic autoantibody profiles. | 06-20-2013 |
20130150379 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS - The present invention provides compostions and methods useful for treating and preventing neurodenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia. | 06-13-2013 |
20130149719 | Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and Their Use as Diagnostic Reagents - The present invention is directed to proteins expressed by | 06-13-2013 |
20130133650 | GAS-BASED TREATMENT FOR INFECTIVE DISEASE - A gas mixture for treatment of a mycobacterial infection and methods thereof, wherein the gas mixture comprises hydrogen. In certain applications, the gas mixture further comprises oxygen and optionally an inert or anaerobic gas, preferably selected from the group consisting of nitrogen, helium, argon, carbon dioxide, and mixtures thereof. The methods for treatment comprise direct inhalation of the gas mixture comprising hydrogen and oxygen, intubation of a patient with a double lumen endotracheal tube thereby supplying one lung with an anaerobic gas, and administration of a gas mixture comprising hydrogen and oxygen in a hyperbaric setting. Also provided is a method of sterilization of a | 05-30-2013 |
20130131313 | EEF2K ASSAYS FOR IDENTIFYING COMPOUNDS THAT INHIBIT EEF2K ACTIVITY - Assays for identifying novel compounds for inhibiting eEF2 kinase and consequence peptides employed therein. | 05-23-2013 |
20130131005 | METHODS AND COMPOSITIONS FOR PROVIDING CARDIAC PROTECTION - The invention provides a method of reducing infarct size and/or limiting, decreasing and/or inhibiting reperfusion injury and/or ameliorating heart failure in a patient comprising administering a pharmaceutically effective amount of at least one compound capable of inhibiting AC5 to the patient. The compound capable of inhibiting AC5 is particularly effective when administered during or after reperfusion in patients suffering from an ischemic injury. | 05-23-2013 |
20130123340 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CARDIAC ISCHEMIC INJURY - Disclosed herein are compositions and methods for the treatment and/or prevention of pathological conditions associated with ischemia/reperfusion injury and/or hypoxic injury of myocardial cell or tissue. | 05-16-2013 |
20130109035 | DETECTION OF HIGH-RISK INTRADUCTAL PAPILLARY MUCINOUS NEOPLASM AND PANCREATIC ADENOCARCINOMA | 05-02-2013 |
20130101623 | ATTENUATED MYCOBACTERIAL STRAIN AS NOVEL VACCINE AGAINST TUBERCULOSIS - The present invention provides a novel attenuated vaccine for tuberculosis. Furthermore, when used as a subcutaneous vaccine, the present invention induces a higher level of protection than the current vaccine. Finally, the present invention results in less tissue damage and a lower number of colony forming units (CFU) in the lungs compared to subjects vaccinated with BCG. | 04-25-2013 |
20130101561 | CLOSED SYSTEM SEPARATION OF ADHERENT BONE MARROW STEM CELLS FOR REGENERATIVE MEDICINE APPLICATIONS - A method for isolating and processing bone marrow derived stem cells, including the steps of: (a) collecting a biological sample containing adherent bone marrow stem cells in a receptacle with interior walls coated with a cell-adherent substrate; (b) incubating the bone marrow cells on the adherent substrate so that a layer of adherent bone marrow stem cells adheres to the substrate; (c) washing any non-adherent cells from the substrate; and (d) collecting the bone marrow stem cell layer. Isolation kits and use of bone marrow cells harvested for cell therapies are also described. | 04-25-2013 |
20130095472 | Cytokines and Genes Differentially Affected by TNF Blockers - The present invention is directed to cytokines and genes that are differentially affected by TNF blockers and the use of these genes and cytokines to help asses the TB risks of new immunosuppressive therapies, to help evaluate the effects of new TB vaccines, and to help assess TB susceptibility in persons exposed to | 04-18-2013 |
20130072398 | Compositions And Methods For Immunodominant Antigens of Mycobacterium Tuberculosis - Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen | 03-21-2013 |
20130071374 | RNA Interferases and Methods of Use Thereof - The present invention is directed to the discovery of a novel family of enzymes designated herein as mRNA interferases that exhibit endoribonuclease activity. The novel finding of the present inventors, therefore, presents new applications for which mRNA interferase nucleic and amino acid sequences, and compositions thereof may be used to advantage. The invention also encompasses screening methods to identify compounds/agents capable of modulating mRNA interferase activity and methods for using such compounds/agents. Also provided is a kit comprising mRNA interferase nucleic and/or amino acid sequences, mRNA interferase activity compatible buffers, and instruction materials. | 03-21-2013 |
20130065866 | DENTINAL DRUG DELIVERY COMPOSITION AND SCREENING METHOD - The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent, a method for using the dentinal drug delivery to provide a dental treatment, and a method for identifying anti-inflammatory agents capable of diffusing through dentin. | 03-14-2013 |
20130052662 | Method for Automated Autoantibody Detection and Identification - The present invention is a kit and method for detecting and identifying autoantibodies. The invention employs the use of indirect immunofluorescence, imaging flow cytometry and pattern recognition software to automatically identify autoantibodies associated with autoimmune disorders. | 02-28-2013 |
20130041009 | Methods and means for increasing resistance to cell damage - Methods are provided to increase resistance to cell damage in a subject. The increase in resistance to cell damage in a subject in the subject is accomplished by decreasing activity of eEF2 kinase in the subject. The eEF2 kinase activity can be decreased by decreasing the amount of functional eEF2 kinase produced by the subject, including contacting the eEF2 kinase with a compound that inhibits phosphorylation of eEF2 kinase substrate or decreasing the amount of functional eEF2 kinase is decreased by reducing expression of a gene encoding the eEF2 kinase. | 02-14-2013 |
20130040385 | HIV-1 LATENCY MODEL FOR HIGH THROUGHPUT SCREENING - Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope. | 02-14-2013 |
20130029426 | Dual Inducible System for the cSPP System - The present invention provides a dual inducible system for single protein production, as well as a method of inducing high level protein expression using amino acids. | 01-31-2013 |
20130022501 | Salivary Bioassay for Early Detection of Bone Loss - The present invention is directed to methods to detect and diagnose osteoporosis and periodontal disease using salivary biomarkers. | 01-24-2013 |
20130011919 | Mammalian alpha-kinase proteins, nucleic acids and diagnostic and therapeutic uses thereof - The present invention provides novel mammalian alpha-kinase proteins: melanoma alpha-kinase (MK), heart alpha-kinase (HK), kidney alpha-kinase (KK), skeletal muscle alpha-kinase (SK), and lymphocyte alpha-kinase (LK). In particular, a novel kinase type is herein provided, characterized by the presence of an alpha-kinase catalytic domain and an ion channel domain. Isolated nucleic acids of the alpha-kinases MK, HK, KK, SK and LK are provided. Methods for making the novel alpha-kinases, cells that express the alpha-kinases and methods for treating an animal in need of either increased or decreased activity of the alpha-kinases are provided. | 01-10-2013 |
20120329790 | Dentinal Drug Delivery Composition - The present invention is a dentinal drug delivery composition composed of cationic and/or neutral porous particles containing an effective amount of a therapeutic agent and a method for using the same to provide a dental treatment. | 12-27-2012 |
20120328684 | CITROBACTER FREUNDII ANTIBACTERIAL AGENTS AND THEIR USE - Provided herein are methods for treating planktonic bacteria or a biofilm. The methods include contacting the planktonic bacteria or biofilm with an effective amount of an isolated | 12-27-2012 |
20120309051 | COMPOSITIONS AND METHODS FOR PREPARING RECOMBINANT MG53 AND METHODS FOR OPTIMIZING SAME - Disclosed herein are nucleic acid sequences that encode novel polypeptides. In particular, the present invention provides nucleic acid molecules that include optimization features that enhance the expression and/or recovery and/or activity of encoded polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins. | 12-06-2012 |
20120295804 | Compositions and Methods for Diagnosis and Treatment of Breast Cancer - The present invention is a population of breast cancer cells with preference for establishing dormancy in bone marrow. The breast cancer cells have characteristics of stem cells and express high levels of Oct4, designated Oct4 | 11-22-2012 |
20120294901 | NOVEL COCHLEATE FORMULATIONS - A process for producing a small-sized, lipid-based cochleates. Cochleates are derived from liposomes which are suspended in an aqueous two-phase polymer solution, enabling the differential partitioning of polar molecule based-structures by phase separation. The liposome-containing two-phase polymer solution, treated with positively charged molecules such as Ca | 11-22-2012 |
20120294800 | TARGETING TUMOR CELLS WITH CHEMOTHERAPEUTIC AGENTS CONJUGATED TO MATRIPTASE ANTIBODIES - The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers. | 11-22-2012 |
20120276068 | METHOD FOR TREATING CHRONIC NERVE TISSUE INJURY USING A CELL THERAPY STRATEGY - A method for treating a degenerative or traumatic injury to a nerve tissue or the brain by administering at or near the injury site a composition containing adherent bone marrow stem cells suspended in a pharmaceutically acceptable liquid in an amount effective to elicit axonal regeneration or re-myelination at the site of injury. | 11-01-2012 |
20120263656 | Natural Polypeptides For Oral Health Care - The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and Statherin fusion proteins (STAT-LF) along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease. | 10-18-2012 |
20120263644 | TREATMENT AND DIAGNOSIS OF INFLAMMATORY DISORDERS AND HIV - This invention concerns compositions and methods of treating or diagnosing inflammatory disorders and other disorders, as well as compositions and methods of treating HIV. | 10-18-2012 |
20120258141 | Methods Of Immune Modulation - The present invention provides compounds and compositions thereof that modulate the immune system. | 10-11-2012 |
20120253280 | CATHETER FOR MINIMALLY INVASIVE CARDIAC PACING SURGERY AND METHOD OF USE - An assembly of a pulmonary venting catheter and a pacing wire disposed therethrough whereby the pacing wire is extended from the distal end of the catheter tube during pacing mode, eliminating the need for exchanging the venting catheter with a pacing catheter to begin pacing after venting. The pacing wire includes a flexible distal end for a first conductor to conductively engage heart tissue after the pacing wire is extended from the catheter distal end; a second conductor, also exposed outside the catheter distal end, completes the circuit. The pacing wire is lockable in unextended and extended positions at the proximal end portion of the assembly. A method for venting and pacing a patient's heart during cardiac surgery is described, which includes retracting the catheter distal end from the pulmonary artery after venting mode, into the right ventricle during pacing mode, whereafter the pacing wire is extended for pacing. | 10-04-2012 |
20120252891 | Vanilloid Fatty Hydroxamates as Therapeutic Anti-inflammatory Pharmaceuticals - Three unique subtypes of N-hydroxyamides and N-hydroxycarbamates containing both the vanilloid moiety (4-hydroxy-3-methoxybenzyl) and a lipophilic aliphatic moiety. Also disclosed are direct syntheses of these vanilloid fatty hydroxamates. The compounds possess inhibitory activity against the enzymes fatty acid amide hydrolase (FAAH) and matrix metallo-proteinase 9 (MMP-9). In addition, these substances bind to the calcium channel protein TRPV1 and inhibit vesicant-induced inflammation in skin and cornea. The compounds have utility in treating topical or systemic inflammatory processes in the skin and/or eye. | 10-04-2012 |
20120238595 | THERAPEUTIC COMPOUNDS - The invention provides compounds of formula (I) wherein u, d, v, m, n, R | 09-20-2012 |
20120237473 | Compositions And Methods For Cell Based Retinal Therapies - The invention relates to pharmaceutical compositions comprising trophic factors, methods to decrease the degeneration of a retina, methods of treating ocular degenerative diseases and methods to select cells for transplantation. | 09-20-2012 |
20120225098 | BIOFILM INHIBITING COMPOSITION - Polysaccharide-containing extracts isolated from a host cell containing nucleotide sequences encoding genes pamA, pamB and pamC, wherein the extract is capable of inhibiting biofilm formation produced by gram-negative bacteria, gram-positive bacteria and fungi, and methods to inhibit biofilm formation or remove biofilms that have already formed. | 09-06-2012 |
20120225093 | Abrogating HIV-1 Infection via Drug-Induced Reactivation of Apoptosis - The present invention relates to compositions and methods of treating, inhibiting, or controlling HIV infection. | 09-06-2012 |
20120220658 | Method for Treating Sepsis or Septic Shock - The present invention is a method for treating sepsis or septic shock using Lipoxin A4. | 08-30-2012 |
20120219737 | Production of extracellular matrix, conditioned media and uses thereof - Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided. Also provided are conditioned media, related compositions, related methods, and related packaging products. | 08-30-2012 |
20120213737 | COMPOSITIONS AND METHODS FOR THERAPEUTIC MEMBRANE REPAIR - Disclosed herein are compositions comprising PTRF polypeptides, nucleic acids, and PTRF binding proteins useful for tissue regeneration and the treatment and prevention of disorders relating to cell membrane damage and repair. | 08-23-2012 |
20120213706 | RECONSTITUTED TUMOR MICROENVIRONMENT FOR ANTICANCER DRUG DEVELOPMENT - Extracellular matrix bioscaffolds capable of supporting the formation and growth of tumors from tumor cells introduced thereto containing tumor associated macrophages and carcinoma-associated fibroblast-like cells cultured under conditions effective to provide a cellular matrix capable of supporting the formation and growth of tumors from tumor cells introduced to the matrix. Bioscaffold kits and methods for using the bioscaffolds for testing, identifying and development of known or novel anti-cancer therapeutics are also disclosed. | 08-23-2012 |
20120202228 | Antibody Profiles Characteristic of Tuberculosis State - Serum antibody assays capable of distinguishing cases of inactive TB from cases of active TB include a combination at least three | 08-09-2012 |
20120196284 | Method of Measuring Telomere Length - Disclosed herein is a novel method of measuring telomere length comprising determining the DNA content (Dx) of a sample, determining the telomeric content (T) of a sample, and determining the value of T/Dx. | 08-02-2012 |
20120149744 | ANTI-MITOTIC ANTI-PROLIFERATIVE COMPOUNDS - Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof. | 06-14-2012 |
20120148491 | METHOD OF OVERCOMING THERAPEUTIC LIMITATIONS OF NONUNIFORM DISTRIBUTION OF RADIOPHARMACEUTICALS AND CHEMOTHERAPY DRUGS - Disclosed is a method for predicting the optimal amounts of radiopharmaceutical and/or chemotherapy agents to administer to a patient, by determining the level of saturation of the therapeutic agents in the patient's cells. The method comprises measuring cellular incorporation of the candidate therapeutic agents in a target cell population on a cell-by-cell basis. The method is able to identify an optimal cocktail of therapeutic agents for treatment of a disease. A method of high-throughput drug discovery incorporating this method, and a 2-stage targeting method of treating a disease using this method are also disclosed. | 06-14-2012 |
20120129912 | RNA Targeting in Alpha-Synucleinopathies - Therapies and assays to screen for small molecules that can have therapeutic use in the control of neurodegenerative diseases such as Parkinson's and other alpha-synucleinopathies. | 05-24-2012 |
20120129165 | IMAGING INDIVIDUAL MRNA MOLECULES USING MULTIPLE SINGLY LABELED PROBES - A method for probing a target sequence of messenger ribonucleic acid molecules (mRNA's) in a fixed, permeabilized cell, said target sequence including at least 30 non-overlapping probe binding regions of 15-100 nucleotides, comprising immersing said cell in an excess of at least 30 nucleic acid hybridization probes, each singly labeled with the same fluorescent label and each containing a nucleic acid sequence that is complementary to a different probe binding region of said target sequence; washing said fixed cell to remove unbound probes; and detecting fluorescence from said probes. | 05-24-2012 |
20120116053 | EXPRESSION OF TRIPLE-HELICAL COLLAGEN-LIKE PRODUCTS IN E.COLI - Recombinant bacterial triple-helical collagen-like proteins comprising two or more repetitive sequences of Gly-Xaa-Yaa yielding high-stability polymeric constructs without the need for post-translational modifications and which may incorporate one or more functional domains of biological or structural importance. The polymers are capable of high-yield production for a variety of applications | 05-10-2012 |
20120115135 | METHOD FOR DETECTION OF ACTIVE PERIODONTAL DISEASE AT THE LOCAL TOOTH SITE - A method for site-specific detection and early diagnosis of periodontal disease using periodontal pocket fluid biomarkers is disclosed. | 05-10-2012 |
20120114603 | IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES - A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions. | 05-10-2012 |
20120107247 | Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their Use as Diagnostic Reagents and Vaccines - The present invention is directed to reagents useful for generating immune responses to | 05-03-2012 |
20120101734 | Method of Predicting Placebo Non-Response - The present invention provides a method of reliably predicting the likelihood of a response to placebo among subjects in, or potentially enrolling in, clinical trials. | 04-26-2012 |
20120093919 | E2F AS A TARGET OF HORMONE REFRACTORY PROSTATE CANCER - The instant invention provides amino acid sequences competing with E2F for DNA binding. Methods of using said amino acid sequences for treatment of hormone-refractory prostate cancer are also provided. | 04-19-2012 |
20120077425 | Accessible Hood Sash - The present invention provides an apparatus and various embodiments thereof which allow the user of a laboratory fume hood to operate equipment and conduct experiments, while keeping the hood sash in a closed position. | 03-29-2012 |
20120071527 | THERAPEUTIC COMPOUNDS - The invention provides compounds of formula I: | 03-22-2012 |
20120059026 | ANTIMICROBIAL AGENTS - The invention provides a compound of formula (I): or a salt or prodrug thereof, wherein Y, W, Z, Z | 03-08-2012 |
20120058056 | TREATMENT OF CUTANEOUS HEMANGIOMA - This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas. | 03-08-2012 |
20120046228 | Methods for Modulating Ovulation - The present invention relates to methods and reagents for modulating ovulation in humans and non-human animals. | 02-23-2012 |
20120045789 | Method for Screening of Antiviral Agents - A method for screening for an antiviral agent capable of blocking a viral viroporin by determining whether a test agent can rescue expression of a fragment of a viral viroporin in a Single Protein Production system of | 02-23-2012 |
20120045429 | Methods and Agent for Modulating the RNA Polymerase II-Histone Surface - The present invention relates to the identification of an intranucleosomal DNA loop formed during transcription through a nucleosome and use of the same to identify an agent that modulates the RNA Polymerase II-histone surface. | 02-23-2012 |
20120039945 | Methods Of Immune Modulation - The present invention provides compounds and compositions thereof that modulate the immune system. | 02-16-2012 |
20120034612 | Methods and Kits for miRNA Isolation and Quantitation - The present invention is a kit and method for isolating and quantitating miRNA and to the use of such methods in the diagnosis and prognosis of disease. | 02-09-2012 |
20120028271 | Methods and Kit for Detecting Breast Cancer - The present inventions relates to kits and methods for diagnosing and monitoring breast cancer. An increase in the level or activity of proteins of the ubiquitin/proteasome pathway, and ancillary proteins thereof, as compared to normal control or benign tissue is indicative of breast cancer. | 02-02-2012 |
20120021984 | Glycoprotein Hormone Analogs - This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha subunit polypeptide and at least one beta subunit polypeptide, wherein the seatbelt region of the beta subunit is linked to the alpha subunit. The invention also provides for a beta subunit polypeptide wherein the C-terminal amino acid is from residue 10 to residue 20 of the seatbelt region. | 01-26-2012 |
20120021033 | DISPERSIN B POLYNUCLEOTIDES AND METHODS OF PRODUCING RECOMBINANT DspB POLYPEPTIDES - Isolated nucleic acid sequences and amino acid sequences for soluble, β-N-acetylglucosaminidase or active fragments or variants thereof which promote detachment of bacterial cells from a biofilm are provided. An isolated mutant bacteria which forms biofilm colonies which tightly adhere to surface but which are unable to release cells into the medium or spread over the surface is also provided. In additions, methods are described for modulating detachment of bacterial cells from biofilm by mutating soluble, β-N-acetylglucosaminidase or altering its expression or activity are also provided. Also provided are compositions, methods and devices for preventing, inhibiting and treating bacterial infections. | 01-26-2012 |
20120016111 | Compositions for the treatment of cancer, and methods for testing and using the same - A composition comprising leukotoxin proteins isolated from a bacterium is provided. In this composition, greater than 85% of the leukotoxin proteins are chemically modified at a basic amino acid residue, and the proteins induce cell death in myeloid leukocytes, while remaining substantially non-toxic to lymphoid leukocytes, lymphocytes, and red blood cells. Also provided is a method of selectively inducing cell death in myeloid leukocytes. The method comprises contacting the myeloid leukocytes with a composition comprising leukotoxin proteins. These leukotoxin proteins may be isolated from the NJ4500 strain of | 01-19-2012 |
20120010152 | Targeting of Podoplanin with Lectin for Use in the Prevention and Treatment of Cancer - Lectin compositions and methods for reducing tumor cell growth and preventing or treating cancer are provided. | 01-12-2012 |
20120003662 | Methods and Kits for Detecting Mastitis - Methods and kits for determining if one or more animals have mastitis and for monitoring animals and the quality of the milk they produce are disclosed. Kits and test assays disclosed are used to determine the quantity of proteasomes and proteins thereof, the activity of proteasome enzymes, the quantity of proteasome bound and regulating proteins, and the quantity of ubiquinated protein. Components and reagents for use in the kits and assays are also disclosed. | 01-05-2012 |
20110319465 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF - A method for preventing, diagnosing, or treating a condition mediated by an estrogen receptor by administering to a patient in need thereof an effective amount of a compound of formula I, II, or a combination thereof: wherein R1, R3, R4, and R5 are independently selected from H, OH, and OR | 12-29-2011 |
20110306751 | Independently Inducible System of Gene Expression - The present invention is directed to the improved methods for the temporal induction of proteins using the condensed single protein production (cSPP) system. | 12-15-2011 |
20110306067 | Antibody Profiles Characteristic of Tuberculosis State - Serum antibody assays capable of distinguishing cases of inactive TB from cases of active TB include a combination at least three | 12-15-2011 |
20110287117 | Adjuvant Therapy in the Treatment of Gouty Arthritis - This invention relates to the treatment of gouty arthritis with cherry juice concentrate. | 11-24-2011 |
20110287015 | MG53 COMPOSITIONS AND METHODS OF USE - Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins. | 11-24-2011 |
20110287004 | MG53 COMPOSITIONS AND METHODS OF USE - Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins. | 11-24-2011 |
20110275596 | METHODS FOR TREATING NEOPLASIA AND FOR IDENTIFYING COMPOSITIONS USEFUL IN SUCH THERAPY - Various methods for treating a patient with neoplasia are disclosed, in particular, methods using topoisomerase Ila-preferential poisons, methods using a combination of a topoisomerase Illi-preferential inhibitor and a topoisomerase II poison, and methods using a combination of a topoisomerase II poison and a proteasome inhibitor are disclosed. Novel topoisomerase Ila-preferential poisons are disclosed, particularly, several novel 13-carboline derivatives are identified. Methods for identifying the novel topoisomerase Ila-preferential poisons and methods for identifying the novel topoisomerase EP-preferential inhibitors are also provided herein. | 11-10-2011 |
20110257034 | METHODS FOR IDENTIFYING GENES WHICH PREDICT DISEASE OUTCOME FOR PATIENTS WITH COLON CANCER - Closures for containers and methods for using same are provided. In a general embodiment/the present disclosure provides a closure having a top portion ( | 10-20-2011 |
20110237519 | Hematopoietic Growth Factor Inducible Neurokinin-1 Gene and Uses Thereof - The present invention discloses the cloning of a new cDNA, HGFIN, from stimulated bone marrow stromal cells that was retrieved with a probe specific for the neurokinin-1 (NK-1) receptor. The novel gene, HGFIN, encodes a protein receptor that is involved in the regulation of hematopoietic proliferation and differentiation. HGFIN is implicated in the treatment of hyperproliferative disorders, particularly bone and breast cancer, because it acts to suppress the proliferating cells. | 09-29-2011 |
20110224407 | Type I Interferon Antagonists - Disclosed in certain embodiments is a method of preparing a Type 1 interferon antagonist comprising modifying a Type 1 interferon at the site of interaction with the interferon receptor subunit IFNAR-1 such that the binding affinity of the interferon to the IFNAR-1 subunit is reduced as compared to the native interferon, and corresponding compositions and methods of treatment thereof. | 09-15-2011 |
20110217282 | Novel Toxin-Antitoxin System - Disclosed in certain embodiments is a method of inhibiting cell function comprising inducing the expression of a mRNA interferase that cleaves mRNA at GCU. | 09-08-2011 |
20110183942 | Methods and Compositions for Treating Alzheimer's Disease - A method is disclosed for inhibiting the build-up of amyloid plaques in the brain of a patient with at least one risk factor for, or a diagnosis of, Alzheimer's Disease by administering to the patient an amount of one or more compounds effective to inhibit the phosphorylative activity of eEF2K, thereby inhibiting amyloid plaque deposition. | 07-28-2011 |
20110172268 | MECHANISM-BASED SMALL-MOLECULE PARASITE INHIBITORS - Methods for preventing or treating an Apicomplexan parasite infection in a patient administering to a patient in need thereof an effective amount of a compound of Formulas I-IV. | 07-14-2011 |
20110171173 | IFN-ALPHA/BETA-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION THROUGH A NOVEL LIGAND-RECEPTOR PAIR: IFN- LIGANDS ENGAGE A NOVEL RECEPTOR IFN-RN (CRF2-12) AND IL-10R2 (CRF2-4) FOR SIGNALING ANDINDUCTION OF BIOLOGICAL ACTIVITIES - A novel IFN-α/β independent ligand receptor system which upon engagement leads, among other things, to the establishment of an anti-viral state is disclosed. Further disclosed are three closely positioned genes on human chromosome 19 that encode distinct but highly homologous proteins, designated IFN-λ1, IFN-λ2, IFN-λ3, based, inter alia, in their ability to induce antiviral protection. Expression of these proteins is induced upon viral infection. A receptor complex utilized by all three IFN-λ proteins for signaling is also disclosed. The receptor complex is generally composed of two subunits, a novel receptor designated IFN-λR1 or CRF2-12, and a second subunit, IL-10R2 or CRF2-4, which is also a shared receptor component for the IL-10 and IL-22 receptor complexes. The gene encoding IFN-λR1 is generally widely expressed, including many different cell types and tissues. Expression of these proteins is induced by immune events, including, for example, upon viral infection. Apoptotosis may also be induced under effective conditions. | 07-14-2011 |
20110105592 | ANTI-SENSE MICRORNA EXPRESSION VECTORS - The present invention relates to an alternative strategy for expressing the antisense sequence of a miRNA. This system allows for continuous production of the antisense sequence and subsequently complete knockdown of the targeted miRNA. | 05-05-2011 |
20110104101 | Immunotherapy for Unresectable Pancreatic Cancer - The present invention provides a novel cancer immunotherapy comprising a vaccination schedule of both intratumoral and systemic injections followed by peripheral boost injection. The immunotherapy can then be followed by other standard treatment as is known in the art for locoregional or metastatic pancreatic cancer. The present invention further provides a kit for administering the cancer immunotherapy described herein. The present invention further provides a method of decreasing the dose of cancer immunotherapy vaccines. | 05-05-2011 |
20110098196 | Multiplex Screening for Pathogenic Hypertrophic Cardiomyopathy Mutations - This invention relates to a new method of screening for hypertrophic cardiomyopathy. In certain embodiments, the invention comprises a method of screening for hypertrophic cardiomyopathy comprising detecting the presence or absence of at least one pathogenic HCM mutation by mutation detection assay in a sample from a subject to be tested for hypertrophic cardiomyopathy. | 04-28-2011 |
20110097722 | Cold Shock Protein Compositions and Methods and Kits for the Use Thereof - The present invention provides cold shock protein-containing compositions for improved DNA synthesis reactions with improved reactivity, methods for synthesizing DNA using such compositions, kits for use in such methods, and DNA compositions yielded by such methods. The present invention further provides cold shock protein-containing compositions for the identification of endoribonuclease cleavage sites, methods for identifying endoribonuclease cleavage sites using such compositions, and kits for use in such methods. | 04-28-2011 |
20110071219 | Hemostatic Effects of Glucono-Delta-Lactone - Glucono-delta-lactone (GDL) can be used to mediate the human blood coagulation process. In particular, GDL can be used in an assay to determine an individual's risk potential for accelerated blood clotting or as a treatment for conditions related to accelerated clotting potential and/or inflammatory states. | 03-24-2011 |
20110059924 | Chemoprevention of Colorectal Cancer by Mesalamine/Sulfasalazine - A method for preventing or treating colorectal cancer in a patient possessing human tropomyocin isoform TC22 is presented. Also presented is a method for evaluating TC22 expression reduction activity of a compound. | 03-10-2011 |
20110052637 | PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS VACCINES - The present invention is directed to proteins expressed by | 03-03-2011 |
20110038854 | STRATEGY FOR HOMO- OR HETERO-DIMERIZATION OF VARIOUS PROTEINS IN SOLUTION AND IN CELL - The present invention describes a chimeric polypeptide comprising a first portion comprising a receptor domain, wherein the receptor domain comprises an intracellular region and a transmembrane region; and a second portion comprising a dimerization domain. The present invention also describes a chimeric polypeptide comprising a first portion comprising a receptor domain, wherein the receptor domain comprises a receptor extracellular region; and a second portion comprising a dimerization domain, wherein the dimerization domain comprises an antibody heavy chain region of a Fab fragment or an antibody light chain region. Polynucleotides encoding the chimeric polypeptides and methods of use of the chimeric polypeptides are also described. | 02-17-2011 |
20110034425 | Method of Treatment for Acute Myelogenous Leukemia - This invention relates to a method of treating acute myelogenous leukemia with TPA along with Dexamethasone and choline magnesium trisalicylate. | 02-10-2011 |
20110021361 | Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids - A method of sorting mixtures of nucleic acid strands comprising hybridizing the strands to an array of immobilized oligonucleotides, each of which includes a constant segment adjacent to a variable segment. The constant segment of the immobilized oligonucleotides can be made complementary to the ends of strands obtained by digesting a double-stranded nucleic acid with a restriction enzyme and restoring the restriction sites, thereby permitting the sorting of strands according to their variable sequences adjacent to their constant terminal restored restriction sites. | 01-27-2011 |
20100255519 | Salivary Bioassay for Early Detection of Bone Loss - The present invention is directed to methods to detect and diagnose osteoporosis and periodontal disease using salivary biomarkers. | 10-07-2010 |
20100228009 | Labeled Biomolecular Compositions and Methods for the Production and Uses Thereof - Disclosed herein is a set of | 09-09-2010 |
20100221246 | METHODS AND COMPOSITIONS FOR TREATING CANCER - The present invention provides methods of treating cancer using 2-amino-6-trifluoromethoxybenzothiazole (riluzole). In one aspect, the present invention provides methods of reducing cancer cell growth. In another aspect, the present invention provides a method of inducing apoptosis in a cancer cell. In another aspect, the present invention provides a method of reducing the growth of a glutamate-releasing tumor. | 09-02-2010 |
20100197509 | Novel oligonucleotide arrays and their use for sorting, isolating, sequencing, and manipulating nucleic acids - A method of sorting mixtures of nucleic acid strands comprising hybridizing the strands to an array of immobilized oligonucleotides, each of which includes a constant segment adjacent to a variable segment. The constant segment of the immobilized oligonucleotides can be made complementary to the ends of strands obtained by digesting a double-stranded nucleic acid with a restriction enzyme and restoring the restriction sites, thereby permitting the sorting of strands according to their variable sequences adjacent to their constant terminal restored restriction sites. | 08-05-2010 |
20100196951 | Antitoxin Destabilization Technology - Disclosed are methods for purifying toxin proteins which avoid denaturation and renaturation procedures. | 08-05-2010 |
20100151004 | MODULATION OF DRUG SENSITIVITY - Methods for the treatment of disorders, including cancer, are described which include administering to a subject a DNA methylation inhibitor and an antineoplastic agent. Compositions containing a DNA methylation inhibitor and an antineoplastic agent, which are useful in treating disorders including cancer, are also described. Additionally, methods useful for developing a prognosis for or diagnosing a subject's development of resistance to treatment with a chemotherapeutic agent are described. | 06-17-2010 |
20100144867 | USE OF LECITHIN:RETINOL ACYL TRANSFERASE GENE PROMOTER METHYLATION IN EVALUATING THE CANCER STATE OF SUBJECT - The present invention relates to a method of evaluating the cancer state of a subject using lecithin:retinol acyl transferase (LRAT) gene promoter methylation status. Methods of analyzing and quantifying LRAT gene promoter methylation level are also disclosed. The present invention also relates to methods of determining the prognosis for s subject having cancer by assessing LRAT mRNA expression and LRAT protein expression. Methods of cancer detection, diagnosis, prognosis, and treatment are also disclosed. | 06-10-2010 |
20100136545 | Cytokines and Genes Differentially Affected by TNF Blockers - The present invention is directed to cytokines and genes that are differentially affected by TNF blockers and the use of these genes and cytokines to help asses the TB risks of new immunosuppressive therapies, to help evaluate the effects of new TB vaccines, and to help assess TB susceptibility in persons exposed to | 06-03-2010 |
20100120118 | MRNA Interferase from Myxococcus Xanthus - A deployment of a toxin gene for developmental programmed cell death in bacteria is described. | 05-13-2010 |
20100075302 | Assays for Resistance to Echinocandin-Class Drugs - Nucleic acid amplification assays for mutations to two short sections of the fungal gene FKS1. Mutations in these target sequences have been shown to correlate with resistance to echinocandin-class drugs. Assays may include detection by sequencing or by labeled hybridization probes. Also, primers, probes and reagent kits for performing such assays. | 03-25-2010 |
20100030382 | INHALABLE PARTICULATE ENVIRONMENTAL ROBOTIC SAMPLER - A robotic sensor measures air quality characteristics as experienced by a toddler, such as a child of six to twelve months in age. The robot includes an air quality sensor, a terrain drive train, a sensor drive train and a control circuit that controls the terrain drive train and the sensor drive train. The control circuit directs the terrain drive train to traverse an area at a speed and a start and stop rate consistent with that of a child and directs the sensor drive train to control the monitoring height at which the air quality sensor measures the air quality characteristic in a manner consistent with that of the child. | 02-04-2010 |
20100017901 | Compositions Comprising MG29 Nucleic Acids, Polypeptides, and Associated Methods of Use - Disclosed herein are compositions and methods for treatment of muscle dysfunction (including sarcopenia) and other diseases involving skeletal muscle, including age-related muscle dysfunction. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the treatment of skeletal muscle disorder, including those related to thr normal aging process. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with altered intracellular Ca2+ regulation and disrupted membrane structure that occurs when the expression levels of MG29 are reduced. | 01-21-2010 |
20100016415 | Proteins Expressed by Mycobacterium Tuberculosis and not by BCG and their use as Diagnostic Reagents and Vaccines - The present invention is directed to reagents useful for generating immune responses to | 01-21-2010 |
20090318348 | Proteins, Nucleic Acids Encoding the Same, and Associated Methods of Use - Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins. | 12-24-2009 |
20090317440 | ANTI-MITOTIC ANTI-PROLIFERATIVE COMPOUNDS - Substituted triazole compounds and pharmaceutical compositions thereof are presented. Also presented are methods for treating a pathology linked to a hyperproliferative disorder by administering the substituted triazole compounds to a patient in need thereof. | 12-24-2009 |
20090306201 | SELECTIVE INHIBITORS FOR TRANSFERASES - A pharmaceutical composition comprising a compound of formula I or II and a pharmaceutically acceptable carrier. Methods for treating a proliferative disorder mediated by a methyl transferase comprising administering an anti-proliferative effective amount of the compound of formula I or II are also presented. | 12-10-2009 |
20090305227 | HIV-1 LATENCY MODEL FOR HIGH THROUGHPUT SCREENING - Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope. | 12-10-2009 |
20090291989 | ISOTHIOCYANATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF - Provided herein are compositions of matter and pharmaceutical compositions thereof, for use in inhibiting the growth of various microbial pathogens, including bacteria, fungi, protozoa, and viral pathogens. Also provided herein are methods of treating microbial diseases/infections and cancer with the compositions. The compositions are additionally useful in wood preservation and food preservation by inhibition of microbial growth. | 11-26-2009 |
20090238801 | AMNION-DERIVED STEM CELLS AND USES THEREOF - The present invention relates to stem cells obtained from the amnion and their methods of obtaining and culturing. The present invention further relates to compositions comprising amnion-derived stems cells (ADSCs) and to methods of using ADSCs. | 09-24-2009 |
20090215120 | The Use of Protein S Fusion for Protein Solubilization - The invention provides vectors containing a multiple cloning site comprising a PrS tag or a PrS2 tag from | 08-27-2009 |
20090209453 | Glycoprotein Hormone Analogs - This invention relates to the field of glycoprotein hormone analogs and their uses as agonists, antagonists, targeting vectors, and immunogens. In particular, this invention describes a method for stabilizing a heterodimer that permits the preparation of functional glycoprotein hormone analogs. The analogs of present invention comprise at least one alpha subunit polypeptide and at least one beta subunit polypeptide, wherein the seatbelt region of the beta subunit is linked to the alpha subunit. The invention also provides for a beta subunit polypeptide wherein the C-terminal amino acid is from residue 10 to residue 20 of the seatbelt region. | 08-20-2009 |
20090163578 | NOVEL MODIFICATION OF IMMUNOMODULATORY PROTEIN - Methods of inhibiting annexin I induced apoptosis by contacting a cell population containing a TRPM7/ChaK1 kinase with an effective amount of a composition containing an inhibitor for the kinase. | 06-25-2009 |
20090118310 | Activated Cdc42-associated kinase (ACK) as a therapeutic target for Ras-induced cancer - Methods for preventing or treating Ras-induced cancer in a patient by (a) detecting v-Ha-Ras-transformed cells in a patient and (b) administering to the patient a therapeutically effective amount of a chemotherapeutic composition comprising an effective amount of an inhibitor for activated Cdc42-associated kinase (ACK) kinase. | 05-07-2009 |
20090098144 | IMMUNOGEN PRESENTING HIV GP120 V3 LOOP IN A CONFORMATION THAT INDUCES BROADLY NEUTRALIZING ANTIBODIES - Insertion of HIV-1 V3 loop peptides from the viral glycoprotein gp120 into selected, immunogenic scaffold proteins results in a recombinant polypeptide that is a potent V3 immunogen. V3 immunogens include natural and consensus V3 sequences and cyclic and reverse peptides. Preferred scaffold proteins are Cholera Toxin subunit B and homologues thereof including closely related | 04-16-2009 |
20090047742 | Inhibition of mRNA Interferase-Induced Apoptosis in BAK-Deficient and BAK- and Bax-Deficient Mammalian Cells - Ribonucleases, antibiotics, bacterial toxins and viruses inhibit protein synthesis, which results in apoptosis in mammalian cells. How the BCL-2 family of proteins regulates apoptosis in response to shutoff of protein synthesis is not known. According to the present invention, an | 02-19-2009 |
20090041751 | Sepsis Prevention Through Adenosine Receptor Modulation - Methods for treating sepsis or septic shock in a patient comprising administering to said patient a therapeutically effective amount of a composition containing an adenosine A | 02-12-2009 |
20090029906 | ERYTHROPOIETIN-DERIVED SHORT PEPTIDE AND ITS MIMICS AS IMMUNO/INFLAMMATORY MODULATORS - The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof. | 01-29-2009 |
20080279846 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS - The present invention provides compostions and methods useful for treating and preventing neurodegenerative disease and neurologically related disorders by inhibition of Lp-PLA2. The compositions and methods are useful for treating and preventing diseases and disorders with abnormal blood brain barrier (BBB) function, for example neurodegenerative diseases with a permeable BBB, such as but not limited to, Alzheimer's Disease, Huntington's Disease, Parkinson's Disease and Vascular Dementia. | 11-13-2008 |
20080274103 | Adenylyl Cyclase Antibodies, Compositions and Uses Thereof - The invention relates to compositions and methods for diagnosing and treating cardiac conditions and neurodegenerative diseases using antibodies which specifically recognize and bind to the adenylyl cyclase 5 isoform in the heart and brain. These antibodies demonstrate high specificity to the AC5 isoform and do not cross react to any other AC5 isoform. The invention further relates to methods of delivery of drugs to the site of injured tissue using the antibodies of the present invention. | 11-06-2008 |